Besides MCL-1 upregulation, other mechanisms of venetoclax resistance have been reported, indicating a genetically diverse landscape among AML patients and heterogeneity of mechanisms used by cells to overcome venetoclax treatment. Here, MCL1 is linked to acute myeloid leukemia.